Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-19
2006-09-19
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S378000, C514S379000, C514S649000, C514S651000
Reexamination Certificate
active
07109198
ABSTRACT:
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
REFERENCES:
patent: 4172896 (1979-10-01), Uno et al.
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 5719197 (1998-02-01), Kanios et al.
patent: 6071537 (2000-06-01), Shank
patent: 6191117 (2001-02-01), Kozachuk
patent: 6323236 (2001-11-01), McElroy
patent: 6437147 (2002-08-01), Andersen et al.
patent: 6506799 (2003-01-01), Dasseux
patent: 6548551 (2003-04-01), Hinz
patent: 2001/0025038 (2001-09-01), Coffin et al.
patent: 2004/0029941 (2004-02-01), Jennings
patent: WO 03/092682 (2003-11-01), None
Gadde et al, “Zonisamide for Weight Loss in Obese Adults”, JAMA 289(14):1820-1825 (2003).
Gadde et al, “Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Woman”, Obesity Research 9(9):544-551 (2001).
Gadde et al, “Zonisamide for Weight Loss in Obese Adults—A Randomized Controlled Trial” JAMA 289(14):1820-1825 (2003).
Gadde et al, “Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Woman”, Obesity Research 9(9):544-551 (2001).
Walker et al, “Chronic Toxicity of the Anticonvulsant Zonisamide in Beagle Dogs”, Fundamental and Applied Toxicology 11:333-342 (1988).
Ayala, “Weight Loss Associated With the Administration of Zonisamide”, AES Proceedings, Epilepsia 41 (Suppl 7):99 (2000)—No. 2.041.
Ayala et al, “Weight Loss Associated With the Administration of Zonisamide”, A Compendium of Posters and Platform Sessions for ZONEGRAN™ and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, Dec. 1-6, 2000, Los Angeles, California.
Morris, III, “The Effect of Zonisamide Administration on Patient Weight”, A Scientific Exhibit at the American Epilepsy Society Annual Meeting, Dec. 3, 2000, Los Angeles, California.
Welty et al, “Weight Loss Associated With Use of Zonisamide in European and US Clinical Trials”, A Compendium of Posters and Platform Sessions for Zonegran®, Presented at the Annual Meeting 2001 of the Aermican Epilepsy Society, Nov. 30-Dec. 5, 2001, Philadelphia, Pennsylvania.
Wilner, “Is Weight Loss With Zonisamide Gender-Specific?”, Dr. Tran, 2002 Annual Meeting of the American Epilepsy Society, https://secure.neurohub.net/cgi-perl/get.cgi?pub=52318&ext=htm.
Ginsberg and Sussman, “Effects of Mood Stabilizers on Weight”, Primary Psychiatry 7(5):49-58 (2000).
Gadde et al, “Zonisamide in Obesity: A 16-Week Randomized Trial”, No. NR473, New Research, American Psychiatric Association 2002 Annual Meeting, May 18-23, 2002, Philadelphia, Pennsylvania.
Gadde et al, “Randomised Trial of Weight Loss Efficacy of Zonisamide”, No. 304, 26(Suppl 1), Aug. 2002, International Journal of Obesity and related metabolic disorders, Journal of the International Association for Study of Obesity, Ninth International Congress on Obesity, Ninth International Congress on Obesity, Sao Paulo, Brazil, Aug. 24-29, 2002.
Gadde et al, “Randomized Controlled Trial of Zonisamide for Treating Obesity”, American Epilepsy Society, http://164.109.45.39/submission/aes/status/..\preview.full.asp?presid=2%2E258, Sep. 11, 2002.
Gadde and Logue, “Bupropion Sustained Release in Obesity: A Randomized Double-Blind, Placebo-Controlled Study”, No. NR634, New Research Program & Abstracts, American Psychiatric Association, 1999 Annual Meeting, The Clinician, May 15-20, 1999, Washington, DC.
Matsuura, “Indication for Anterior Temporal Lobectomy in Patients with Temporal Lobe Epilepsy and Psychopathology”, Epilepsia 41(Suppl. 9):39-42 (2000).
Grady, “Quest for Weight-Loss Drug Takes an Unusual Turn”, The New York Times—Health, www.nytimes.com, Mar. 15, 2003.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Complaint and Jury Demand, Filed Jun. 14, 2004, United States District Court for the Middle District of North Carolina.
Duke University and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,First Amended Complaint and Jury Demand, Filed Jul. 12, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Defendant Eisai Inc.'s Motion to Dismiss for Lack of Subject Matter Jurisdiction and for Failure to State a Claim for Which Relief can be Granted, Filed Aug. 13, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Memorandum in Support of Defendant Eisai Inc.'s Motion to Dismiss, Filed Aug. 13, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Elan Pharmaceuticals', Elan Corporations's, and Julianne Jennings' Motion to Strike Pursuant to Fed. R. Civ. Pro. 12(f), Filed Aug. 13, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Elan Pharmaceuticals', Elan Corporation's, and Julianne Jennings' Motion For Stay, Filed Aug. 13, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Elan Corporation's Motion to Dismiss for Lack of Personal Jurisdiction Pursuant to Fed. R. Civ. Pro. 12(b)(2), Filed Aug. 13, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Elan Pharmaceuticals', Elan Corporations', and Julianne Jennings' Brief in Support of Motion to Dismiss, Motion to Strike, and Motion for Stay, Filed Aug. 13, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Duke University and Orexigen Therapeutics, Inc. Non-Opposition to Elan Pharmaceuticals, Elan Corporations', and Julianne Jennings' Motion to Strike, Filed Sep. 7, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Plaintiffs' Opposition to the Motions to Dismiss and Motion to Stay of Defendants Elan Corporation PLC, Elan Pharmaceuticals, Inc. and Julianne Jennings, Filed Sep. 7, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Plaintiffs' Opposition to Defendant Eisai Inc.'s Motion to Dismiss for Lack of Subject Matter Jurisdiction and for Failure to State a Claim for which Relief can be Granted, Filed Sep. 7, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,Reply Brief in Support of Defendant Eisai Inc.'s Motion to Dismiss, Filed Sep. 24, 2004, United States District Court for the Middle District of North Carolina.
Duke University, and Orexigen Therapeutics, Inc. V. Elan Corporation et al. Civil Action No. 1:04CV00532,The Elan Defendants' Reply Brief in Support of Motions to Dismiss, Strike and Motion f
Gadde Kishore M.
Krishnan K. Ranga R.
Duke University
Jones Dwayne
Knobbe Martens Olson and Bear LLP
LandOfFree
Method for treating obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598401